Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib in wAIHA (FORWARD)
NCT03764618Phase 3Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Apr 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of fostamatinib in warm antibody autoimmune hemolytic anemia (WAIHA), sponsored by Rigel Pharmaceuticals, Inc.. Started Apr 2019; status: completed.
02
Drugs
fostamatinib
03
Conditions
warm antibody autoimmune hemolytic anemia (WAIHA)
Beyond the preview
Go deeper on NCT03764618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764618.